Mustang Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

License Agreements, Clinical Research Support Agreements and Sponsored Research Agreements (Details Textual)

License Agreements, Clinical Research Support Agreements and Sponsored Research Agreements (Details Textual) - USD ($)		1 Months Ended								10 Months Ended	12 Months Ended
	Jul. 03, 2017	Nov. 20, 2017	May 31, 2017	Mar. 31, 2017	Mar. 17, 2017	Feb. 28, 2017	Oct. 31, 2016	Apr. 30, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Nov. 28, 2017	Jul. 31, 2016
Research And Development Expense, Sponsored Research Payment													$ 800,000
Research and Development Expense											$ 100,000
Common Stock, Shares, Outstanding											25,236,255	15,165,244
Professional Fees											$ 120,000	$ 120,000
Stock Issued During Period, Value, Purchase of Assets										$ 147,000	$ 1,682,000
Proceeds from Issuance of Private Placement							$ 10,000,000
Common Stock, Shares Authorized											50,000,000	50,000,000
Psca Technology License [Member]
Payment Of Upfront Fees			$ 300,000
Revenue Recognition Milestone Method Payments Due			14,900,000
Maintenance Costs			50,000
Cs Technology License [Member]
Payment Of Upfront Fees			600,000
Revenue Recognition Milestone Method Payments Due			14,900,000
Maintenance Costs			50,000
IL13Ra2 [Member]
Research and Development Expense											$ 1,400,000
Harvard College License [Member]
Payment Of Upfront Fees		$ 300,000
Other Commitment, Due in Next Twelve Months		25,000
Other Commitment, Due in Third Year		100,000
Other Commitment, Due in Second Year		50,000
Development Milestones Method Additional Payments Due		$ 16,700,000
CD123 CRA [Member]
Research and Development Expense											$ 1,400,000
Stephen Forman [Member]
Annual Consulting Fees												$ 60,000
Christine Brown [Member]
Annual Consulting Fees												60,000
University of California [Member]
Development Milestones Method Additional Payments Due					$ 14,300,000
University of California [Member] \| UCLA License [Member]
Payment Of Upfront Fees					200,000
Other Commitment, Due in Next Twelve Months					15,000
Other Commitment, Due in Fifth Year					50,000
Other Commitment, Due in Fourth Year					$ 25,000
City Of Hope [Member]
Revenue Recognition Milestone Method Payments Due						$ 100,000
Stock Issued During Period, Shares, Purchase of Assets											293,588
Payments for Other Fees				$ 100,000
City Of Hope [Member] \| Intellectual Property [Member]
Payment Of Upfront Fees								$ 2,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners									10.00%
Stock Issued During Period, Shares, Purchase of Assets									1,000,000
City Of Hope [Member] \| Intellectual Property [Member] \| Maximum [Member]
Royalty Expense									$ 1,000,000
City Of Hope [Member] \| Commitment One [Member] \| Intellectual Property [Member]
Development Milestones Method Additional Payments Due									2,000,000
City Of Hope [Member] \| Commitment Two [Member] \| Intellectual Property [Member]
Development Milestones Method Additional Payments Due									14,500,000
City Of Hope [Member] \| AR CD123 License [Member]
Payment Of Upfront Fees						19,450
Revenue Recognition Milestone Method Payments Due						14,500,000
Research And Development Expense, Sponsored Research Payment						200,000
Research and Development Expense											$ 0
Licensing Arrangements Additional Costs Incurred						97,490
Maintenance Costs						25,000
City Of Hope [Member] \| IL License [Member]
Revenue Recognition Milestone Method Payments Due						14,500,000
Maintenance Costs						25,000
City Of Hope [Member] \| Her2 Technology License [Member]
Payment Of Upfront Fees			600,000
Revenue Recognition Milestone Method Payments Due			14,900,000
Maintenance Costs			$ 50,000
City Of Hope [Member] \| Spacer License [Member]
Maintenance Costs						10,000
City Of Hope [Member] \| IL13Ra2 [Member]
Payment Of Upfront Fees						9,300
Research And Development Expense, Sponsored Research Payment						200,000
Research and Development Expense											0
Licensing Arrangements Additional Costs Incurred						$ 100,000
City Of Hope [Member] \| Sponsored Research Agreement [Member]
Research and Development Expense									$ 2,000,000	$ 1,500,000	2,000,000	$ 2,000,000
Fred Hutchinson Cancer Research Center [Member] \| CD20 Technology License [Member]
Payment Of Upfront Fees	$ 300,000
Maintenance Costs	50,000
Development Milestones Method Additional Payments Due	39,100,000
Fred Hutchinson Cancer Research Center [Member] \| CD20 Clinical Agreement [Member]
Research And Development Expense, Sponsored Research Payment	$ 5,300,000
Research and Development Expense											$ 600,000
Common Class A [Member]
Stock Issued During Period, Shares, Purchase of Assets										1,000,000	0
Common Stock, Shares, Outstanding											1,000,000	1,000,000
Noncontrolling Interest, Ownership Percentage by Parent											5.00%
Stock Issued During Period, Value, Purchase of Assets										$ 0	$ 0
Common Stock, Shares Authorized												1,000,000		1,000,000
Common Class A [Member] \| City Of Hope [Member]
Stock Issued During Period, Shares, Purchase of Assets							293,588
Common Class A [Member] \| City Of Hope [Member] \| Market Approach Valuation Technique [Member]
Stock Granted During Period, Value Per Share Determined							$ 5.73
Stock Issued During Period, Value, Purchase of Assets							$ 1,700,000
Common Class A [Member] \| City Of Hope [Member] \| Intellectual Property [Member]
Research and Development Expense										$ 100,000
Stock Granted During Period, Valuation Inputs, Weighted Marketability Rate									44.80%
Stock Granted During Period, Valuation Inputs, Weighted Average Cost of Capital									30.00%
Common Class A [Member] \| City Of Hope [Member] \| Intellectual Property [Member] \| Discounted Cash Flow Model [Member]
Stock Granted During Period, Value Per Share Determined									$ 0.147
Stock Issued During Period, Value, Purchase of Assets									$ 100,000